MORGAN STANLEY: Here are the 10 healthcare companies that are most likely to get acquired in the next 12 months

Ticker: BMRN

Company summary: BioMarin focuses on developing treatments for rare diseases. It recently launched Palynziq, which treats adult phenylketonuria, a rare inherited disorder in which the body can't process an amino acid called phenylalanine. Its pipeline also includes vosoritide (treats achondroplasia, a type of short-limbed dwarfism), val-rox (hemophilia A gene therapy), and BMN250 (treats Sanfilippo Syndrome B).

Market cap: $17.6 billion

Ticker: SGEN

Company summary: Seattle Genetics is a biotech company that develops treatments for cancer. Its lead product is Adcetris, which treats different forms of blood and lymphatic cancers.

Market cap: $12.9 billion

Ticker: DVA

Company summary: DaVita is a dialysis clinic operator that services patients with chronic kidney failure and late stage renal disease.

Market cap: $12.4 billion

Ticker: UHS

Company summary: Universal Health Services owns and operates acute care hospitals, outpatient facilities, and behavioral healthcare facilities.

Market cap: $11.7 billion

Ticker: DXCM

Company summary: Dexcom makes and sells glucose monitoring devices for diabetic patients.

Market cap: $11.5 billion

Ticker: NBIX

Company summary: Neurocrine Biosciences makes pharmaceutical products for neurological and endocrine-related diseases and disorders.

Market cap: $10.8 billion

Ticker: PRGO

Company summary: Perrigo mainly manufactures over-the-counter medications.

Market cap: $9.8 billion

Ticker: NKTR

Company summary: Nektar is a pharmaceutical company that creates drugs to treat cancer, chronic pain and auto-immune disease.

Market cap: $9.5 billion

Ticker: SRPT

Company summary: Sarepta Therapeutics focuses on developing treatments for rare neuromuscular diseases. Its lead product is Exondys, which treats Duchenne muscular dystrophy.

Market cap: $9.5 billion